With 2,000 sq. feet of dedicated R&D space in our state-of-the-art facility in Rochester, MN, Nucleus RadioPharma has the capacity and ability to prioritize your radiotherapy or theranostic product development, regardless of the isotope.
Research & Development
Accelerate radiopharmaceutical development and pre-clinical research in a controlled environment
- 2,000 sq. feet
of R&D space - Opened:
September 5, 2024
Development and formulation:
- Radiolabeling procedures
- Chelation of radioisotopes to antibodies, peptides, mini-proteins, and small molecules
- Specifications development
- Ensure processes and analytical methods meet regulatory requirements
- Radiopharmaceutical technology transfer
Stability program management:
- Lead formulation and analytical development for improved stability
- Drug stability testing under real-world storage and transportation conditions
- Shelf-life validation to meet regulatory and clinical requirements
Why Nucleus Radiopharma for your radiotherapy and theranostic R&D needs?
- Isotope-agnostic approach tailored to your therapeutic and diagnostic needs
- Seamless R&D-to-manufacturing transition with space dedicated to early-stage formulation and process refinement
- Regulatory-ready development with built-in quality and safety exceeding industry standards
